KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Emergent BioSolutions (EBS) Gross Profit (2016 - 2025)

Historic Gross Profit for Emergent BioSolutions (EBS) over the last 17 years, with Q3 2025 value amounting to $145.2 million.

  • Emergent BioSolutions' Gross Profit fell 1518.69% to $145.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $834.9 million, marking a year-over-year increase of 202.86%. This contributed to the annual value of $767.6 million for FY2024, which is 321.37% up from last year.
  • As of Q3 2025, Emergent BioSolutions' Gross Profit stood at $145.2 million, which was down 1518.69% from $74.0 million recorded in Q2 2025.
  • Emergent BioSolutions' Gross Profit's 5-year high stood at $534.3 million during Q4 2022, with a 5-year trough of $11.4 million in Q1 2023.
  • In the last 5 years, Emergent BioSolutions' Gross Profit had a median value of $163.5 million in 2024 and averaged $216.4 million.
  • In the last 5 years, Emergent BioSolutions' Gross Profit plummeted by 9492.2% in 2023 and then soared by 126666.67% in 2024.
  • Over the past 5 years, Emergent BioSolutions' Gross Profit (Quarter) stood at $292.4 million in 2021, then surged by 82.73% to $534.3 million in 2022, then fell by 8.05% to $491.3 million in 2023, then decreased by 1.89% to $482.0 million in 2024, then crashed by 69.88% to $145.2 million in 2025.
  • Its Gross Profit was $145.2 million in Q3 2025, compared to $74.0 million in Q2 2025 and $133.7 million in Q1 2025.